Inflammatory Bowel Disease (IBD), which includes Crohn’s disease and ulcerative colitis, affects millions of people worldwide and is known for its unpredictable nature, fluctuating symptoms, and highly individualized disease progression. Despite major advances in biologic therapies and small-molecule drugs, many patients still experience treatment failure, relapse, or persistent inflammation. A recent review by Stefan Schreiber, Konrad Aden, Florian Tran, and Philip Rosenstiel published in Gut explores whether precision medicine can finally deliver more personalized and effective care for people living with IBD.
The review highlights one of the biggest challenges in IBD treatment: no two patients experience the disease in exactly the same way. Even within the same patient, disease activity and treatment response can change significantly over time. Unlike cancer care, where specific genetic mutations often guide targeted therapies, IBD lacks dominant molecular markers that can reliably predict how a patient will respond to treatment.
Although the number of available therapies for IBD has expanded rapidly in recent years, clinicians still struggle to determine which treatment will work best for individual patients before therapy begins. The authors explain that predictive biomarkers — biological indicators capable of forecasting treatment response — remain limited and inconsistent in IBD care.
The paper argues that current approaches to evaluating treatment success are also too simplistic. Traditional models often classify patients as either “responders” or “non-responders” based on a single assessment at one point in time. According to the authors, this binary system fails to capture the complex and evolving nature of chronic inflammatory disease.
Instead, the researchers propose a more dynamic and individualized approach centered around “comprehensive disease control.” This model would combine multiple indicators of patient health, including symptom improvement, inflammation monitoring, molecular profiling, and patient-reported outcomes over time.
The review also introduces the idea of continuously monitoring low levels of residual inflammation, similar to how oncology tracks minimal residual disease in cancer patients. The authors suggest that ongoing molecular monitoring and real-time assessment of treatment response could help clinicians identify worsening disease earlier, adjust therapies more quickly, and potentially prevent long-term complications before symptoms become severe.
Importantly, the study highlights the growing role of longitudinal data and artificial intelligence-driven analytics in shaping the future of precision medicine. Continuous tracking of disease patterns, treatment responses, and biological changes may eventually help healthcare providers tailor therapies more accurately and proactively for each patient.
The researchers further argue that precision medicine in IBD should not focus solely on selecting the right drug. It should also involve adaptive treatment strategies, combination therapies, and individualized monitoring systems that evolve alongside the patient’s condition.
ThinkSpace Insights
1. Move Toward Dynamic and Personalized Disease Monitoring
Healthcare systems should adopt continuous monitoring approaches that track inflammation, treatment response, and patient-reported outcomes over time rather than relying on single-point evaluations.
2. Invest in Biomarker and Molecular Profiling Research
Further research is needed to identify reliable predictive biomarkers that can help clinicians personalize IBD treatment decisions before therapy begins.
3. Integrate Artificial Intelligence and Data Analytics into IBD Care
AI-driven analysis of longitudinal patient data could improve early prediction of treatment response, disease progression, and therapeutic adjustments.
4. Prioritize Comprehensive Disease Control Over Symptom Suppression
Treatment goals should move beyond temporary symptom relief toward broader measures of long-term disease stability, inflammation control, and quality of life.
5. Encourage Proactive Rather Than Reactive Care Models
Early intervention, ongoing monitoring, and adaptive treatment adjustments may help reduce complications, hospitalizations, and long-term disease burden for patients living with IBD.
The review ultimately suggests that precision medicine in IBD remains promising but incomplete. While major scientific and technological advances are expanding the possibilities for individualized care, significant challenges remain in identifying reliable biomarkers and translating complex molecular data into practical clinical decisions.
Still, the authors argue that the future of IBD care may lie in shifting from reactive treatment toward proactive, data-driven disease management. By combining continuous monitoring, molecular profiling, personalized therapeutic adjustments, and patient-centered care, precision medicine could eventually transform how chronic inflammatory diseases are managed and improve long-term outcomes for millions of patients worldwide.
Read Abstract via https://gut.bmj.com/content/75/1/176
